Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis

NCT00043329 is registered in ClinicalTrials.gov with InterMune as lead sponsor.

NCT NCT00043329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00043329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis
Lead sponsor
InterMune
Phase
Observational
Overall status
Completed
Start date
January 31, 2002
Completion date
September 30, 2005
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteopetrosis